Regeneron/Sanofi’s PSCK9 Inhibitor Might Need Two-Week Dosing Schedule

Fully human antibody for hypercholesterolemia is set to enter Phase III next month, and while the firms aren’t discussing the protocol, recent data suggest that REGN727/SRA236553 may need dosing every two weeks, rather than the more convenient monthly schedule.